Financhill
Sell
37

PSTV Quote, Financials, Valuation and Earnings

Last price:
$0.66
Seasonality move :
-6.51%
Day range:
$0.59 - $0.67
52-week range:
$0.24 - $2.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.81x
P/B ratio:
--
Volume:
918.6K
Avg. volume:
3M
1-year change:
-70.54%
Market cap:
$11.2M
Revenue:
--
EPS (TTM):
-$2.53

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PSTV
Plus Therapeutics
$1.4M -$0.26 -- -54.22% $9.83
CATX
Perspective Therapeutics
$123.9K -$0.35 -- -35.77% $14.3929
RVP
Retractable Technologies
-- -- -- -- --
VNRX
VolitionRX
$1.3M -$0.04 197.5% -46.88% $2.92
VTAK
Catheter Precision
$1.2M -$0.14 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.1M -$0.01 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PSTV
Plus Therapeutics
$0.66 $9.83 $11.2M -- $0.00 0% 0.81x
CATX
Perspective Therapeutics
$2.3500 $14.3929 $174M -- $0.00 0% 15.21x
RVP
Retractable Technologies
$0.75 -- $22.5M -- $0.00 0% 0.68x
VNRX
VolitionRX
$0.50 $2.92 $49.2M -- $0.00 0% 35.08x
VTAK
Catheter Precision
$0.29 -- $2.7M 0.40x $0.00 0% 1.97x
XTNT
Xtant Medical Holdings
$0.50 $1.75 $70.2M -- $0.00 0% 0.58x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PSTV
Plus Therapeutics
-- -0.140 -- --
CATX
Perspective Therapeutics
-- -1.032 -- --
RVP
Retractable Technologies
1.55% -0.347 11.72% 5.80x
VNRX
VolitionRX
-28.76% 1.111 8.83% 0.19x
VTAK
Catheter Precision
12% -1.682 128.21% 0.53x
XTNT
Xtant Medical Holdings
44.29% -0.806 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PSTV
Plus Therapeutics
-- -$3.8M -- -- -- -$3.7M
CATX
Perspective Therapeutics
-- -$20.9M -- -- -- -$41.2M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

Plus Therapeutics vs. Competitors

  • Which has Higher Returns PSTV or CATX?

    Perspective Therapeutics has a net margin of -- compared to Plus Therapeutics's net margin of --. Plus Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PSTV
    Plus Therapeutics
    -- -$0.37 --
    CATX
    Perspective Therapeutics
    -- -$0.61 --
  • What do Analysts Say About PSTV or CATX?

    Plus Therapeutics has a consensus price target of $9.83, signalling upside risk potential of 1389.9%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 512.46%. Given that Plus Therapeutics has higher upside potential than Perspective Therapeutics, analysts believe Plus Therapeutics is more attractive than Perspective Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PSTV
    Plus Therapeutics
    1 1 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is PSTV or CATX More Risky?

    Plus Therapeutics has a beta of 0.878, which suggesting that the stock is 12.185% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

  • Which is a Better Dividend Stock PSTV or CATX?

    Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PSTV or CATX?

    Plus Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Plus Therapeutics's net income of -$2.9M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.81x versus 15.21x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PSTV
    Plus Therapeutics
    0.81x -- -- -$2.9M
    CATX
    Perspective Therapeutics
    15.21x -- -- -$40.2M
  • Which has Higher Returns PSTV or RVP?

    Retractable Technologies has a net margin of -- compared to Plus Therapeutics's net margin of -18.58%. Plus Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    PSTV
    Plus Therapeutics
    -- -$0.37 --
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About PSTV or RVP?

    Plus Therapeutics has a consensus price target of $9.83, signalling upside risk potential of 1389.9%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Plus Therapeutics has higher upside potential than Retractable Technologies, analysts believe Plus Therapeutics is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    PSTV
    Plus Therapeutics
    1 1 0
    RVP
    Retractable Technologies
    0 0 0
  • Is PSTV or RVP More Risky?

    Plus Therapeutics has a beta of 0.878, which suggesting that the stock is 12.185% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.650, suggesting its more volatile than the S&P 500 by 64.995%.

  • Which is a Better Dividend Stock PSTV or RVP?

    Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

  • Which has Better Financial Ratios PSTV or RVP?

    Plus Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Plus Therapeutics's net income of -$2.9M is lower than Retractable Technologies's net income of -$1.9M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.81x versus 0.68x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PSTV
    Plus Therapeutics
    0.81x -- -- -$2.9M
    RVP
    Retractable Technologies
    0.68x -- $10.3M -$1.9M
  • Which has Higher Returns PSTV or VNRX?

    VolitionRX has a net margin of -- compared to Plus Therapeutics's net margin of -1226.82%. Plus Therapeutics's return on equity of -- beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PSTV
    Plus Therapeutics
    -- -$0.37 --
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About PSTV or VNRX?

    Plus Therapeutics has a consensus price target of $9.83, signalling upside risk potential of 1389.9%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 484.8%. Given that Plus Therapeutics has higher upside potential than VolitionRX, analysts believe Plus Therapeutics is more attractive than VolitionRX.

    Company Buy Ratings Hold Ratings Sell Ratings
    PSTV
    Plus Therapeutics
    1 1 0
    VNRX
    VolitionRX
    2 1 0
  • Is PSTV or VNRX More Risky?

    Plus Therapeutics has a beta of 0.878, which suggesting that the stock is 12.185% less volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

  • Which is a Better Dividend Stock PSTV or VNRX?

    Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PSTV or VNRX?

    Plus Therapeutics quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $474.5K. Plus Therapeutics's net income of -$2.9M is higher than VolitionRX's net income of -$5.8M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.81x versus 35.08x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PSTV
    Plus Therapeutics
    0.81x -- -- -$2.9M
    VNRX
    VolitionRX
    35.08x -- $474.5K -$5.8M
  • Which has Higher Returns PSTV or VTAK?

    Catheter Precision has a net margin of -- compared to Plus Therapeutics's net margin of -4291.67%. Plus Therapeutics's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    PSTV
    Plus Therapeutics
    -- -$0.37 --
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About PSTV or VTAK?

    Plus Therapeutics has a consensus price target of $9.83, signalling upside risk potential of 1389.9%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 599.3%. Given that Plus Therapeutics has higher upside potential than Catheter Precision, analysts believe Plus Therapeutics is more attractive than Catheter Precision.

    Company Buy Ratings Hold Ratings Sell Ratings
    PSTV
    Plus Therapeutics
    1 1 0
    VTAK
    Catheter Precision
    0 0 0
  • Is PSTV or VTAK More Risky?

    Plus Therapeutics has a beta of 0.878, which suggesting that the stock is 12.185% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.870, suggesting its less volatile than the S&P 500 by 187.02%.

  • Which is a Better Dividend Stock PSTV or VTAK?

    Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PSTV or VTAK?

    Plus Therapeutics quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $96K. Plus Therapeutics's net income of -$2.9M is higher than Catheter Precision's net income of -$4.1M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.81x versus 1.97x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PSTV
    Plus Therapeutics
    0.81x -- -- -$2.9M
    VTAK
    Catheter Precision
    1.97x 0.40x $96K -$4.1M
  • Which has Higher Returns PSTV or XTNT?

    Xtant Medical Holdings has a net margin of -- compared to Plus Therapeutics's net margin of -10.04%. Plus Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    PSTV
    Plus Therapeutics
    -- -$0.37 --
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About PSTV or XTNT?

    Plus Therapeutics has a consensus price target of $9.83, signalling upside risk potential of 1389.9%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 246.78%. Given that Plus Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Plus Therapeutics is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    PSTV
    Plus Therapeutics
    1 1 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is PSTV or XTNT More Risky?

    Plus Therapeutics has a beta of 0.878, which suggesting that the stock is 12.185% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

  • Which is a Better Dividend Stock PSTV or XTNT?

    Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PSTV or XTNT?

    Plus Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Plus Therapeutics's net income of -$2.9M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.81x versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PSTV
    Plus Therapeutics
    0.81x -- -- -$2.9M
    XTNT
    Xtant Medical Holdings
    0.58x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Are We Heading Toward a Recession?
Are We Heading Toward a Recession?

Fears of a recession in 2025 grew at the end…

3 Recession-Proof ETFs to Invest in Now
3 Recession-Proof ETFs to Invest in Now

The U.S. gross domestic product (GDP) contracted 0.3% during the…

Is Butterfly Network the Best Small-Cap Stock?
Is Butterfly Network the Best Small-Cap Stock?

Brought to public trading by an SPAC merger in early…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 10

Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.

Buy
97
NGVC alert for May 10

Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.

Sell
38
ONTO alert for May 10

Onto Innovation [ONTO] is down 30.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock